	AAeARx:HypertensionDrugs

AAeARx:HypertensionDrugs

このアプリは現在ストアで閲覧することができません。
	価格	240円	ダウンロード
	ｼﾞｬﾝﾙ	メディカル
	サイズ	3.6MB
	開発者	First Line Medical Communications Ltd
	順位	ｼﾞｬﾝﾙ別： --- 総合： ---
	ﾘﾘｰｽ日	2010-05-02 11:47:43
	評価	評価が取得できませんでした。
	互換性	iOS 4.3以降が必要です。 iPhone、iPad および iPod touch 対応。
2024-04-26　このアプリは現在ストアから情報が取得できません。削除された可能性があります。

Up-to-date (to January 31, 2013) accurate information to Avoid Adverse Effects in Adults when using Hypertension Drugs (AAeARx:HypertensionDrugs). The interface is easy and intuitive to navigate, rainbow colour-coded, searchable, zoomable, viewable in portrait and landscape, with a bookmark for archiving favourites. Access any of the 59 drugs in the 9 groups of antihypertensive drugs with different mechanisms of action through the memorable rainbow home page or through Quick Find. Touch on any of the 5 icons at the base of the screen to rapidly access clear, concise, and consistently presented drug information (CC: cautions, contraindications, indications; DI: drug interactions; AE: adverse effects, M: mechanism of action; D: dosage and overdose). Internet access is not required.

Really useful hyperlinks are provided throughout to a Glossary and Rapid References on CYP3A4 inhibitors/ inducers; Drugs that lower BP; Drugs that increase blood K; Surgery and anaesthesia).

Developed and designed to make prescribing, using, and understanding hypertension drugs easy and effective, and to Avoid Adverse Effects in Adults for doctor, nurse, and other prescribers, medical and biomedical science students, and users of drugs for hypertension, by experienced medical editor, UK-registered Dr Lindy van den Berghe. All information has been checked for accuracy against the latest Summaries of Product Characteristics (SPCs) provided by drug companies on their websites and through http://www.medicines.org.uk/emc/. Free updates incorporating new information provided in updated SPCs will be available every 3 months from the App Store.

更新履歴
Updated to incorporate all new information in Summaries of Product Characteristics to January 31, 2013 and includes 2 new ACE inhibitors (benazepril hydrochloride and zofenopril calcium) and 1 new AIIR blocker (azilsartan medoxomil)